Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era DOI Creative Commons
Zhan Wang,

Luwei Li,

Shuai Yang

и другие.

Frontiers in Microbiology, Год журнала: 2024, Номер 15

Опубликована: Окт. 8, 2024

Since December 2019, coronavirus disease 2019 (COVID-19) has been spreading worldwide with devastating immediate or long-term effects on people’s health. Although the lungs are primary organ affected by COVID-19, individuals infected SARS-CoV-2 also develop systemic lesions involving multiple organs throughout body, such as cardiovascular system. Emerging evidence reveals that COVID-19 could generate myocardial fibrosis, termed “COVID-19-associated fibrosis.” It can result from activation of fibroblasts via renin-angiotensin-aldosterone system (RAAS), transforming growth factor-β1 (TGF-β1), microRNAs, and other pathways, occur in cellular interactions SARS-CoV-2, immunocytes, endothelial cells. Nonetheless, to gain a more profound insight into natural progression COVID-19-related additional investigations necessary. This review delves underlying mechanisms contributing COVID-19-associated fibrosis while examining antifibrotic potential current treatments, thereby offering guidance for future clinical trials these medications. Ultimately, we propose research directions post-COVID-19 era, artificial intelligence (AI) telemedicine. We recommend relevant tests be added follow-up patients detect promptly.

Язык: Английский

Editorial: Methods in cardiovascular biologics and regenerative medicine DOI Creative Commons
Narasimman Gurusamy, Olaf Bergmann, Clotilde Castaldo

и другие.

Frontiers in Cardiovascular Medicine, Год журнала: 2024, Номер 11

Опубликована: Сен. 13, 2024

Язык: Английский

Процитировано

1
Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era DOI Creative Commons
Zhan Wang,

Luwei Li,

Shuai Yang

и другие.

Frontiers in Microbiology, Год журнала: 2024, Номер 15

Опубликована: Окт. 8, 2024

Since December 2019, coronavirus disease 2019 (COVID-19) has been spreading worldwide with devastating immediate or long-term effects on people’s health. Although the lungs are primary organ affected by COVID-19, individuals infected SARS-CoV-2 also develop systemic lesions involving multiple organs throughout body, such as cardiovascular system. Emerging evidence reveals that COVID-19 could generate myocardial fibrosis, termed “COVID-19-associated fibrosis.” It can result from activation of fibroblasts via renin-angiotensin-aldosterone system (RAAS), transforming growth factor-β1 (TGF-β1), microRNAs, and other pathways, occur in cellular interactions SARS-CoV-2, immunocytes, endothelial cells. Nonetheless, to gain a more profound insight into natural progression COVID-19-related additional investigations necessary. This review delves underlying mechanisms contributing COVID-19-associated fibrosis while examining antifibrotic potential current treatments, thereby offering guidance for future clinical trials these medications. Ultimately, we propose research directions post-COVID-19 era, artificial intelligence (AI) telemedicine. We recommend relevant tests be added follow-up patients detect promptly.

Язык: Английский

Процитировано

0